LXRs, Cholesterol Metabolism and Uterine Dystocia

The Role of Two Nuclear Receptors for Oxysterols as a Molecular Cause of Uterine Dystocia: LXR Alpha and LXR Beta

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01107158

Enrollment

Registered

2010-04-20

Start date

2010-04-30

Completion date

2015-09-03

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystocia, Uterine Inertia

Brief summary

Despite the fact that a link between cholesterol and the myometrium has been clearly established, no study investigating aspects of cholesterol metabolism and uterine dystocia currently exists. This study is a pilot study whose aim is to test the hypothesis that an association between uterine dystocia and single-nucleotide polymorphisms (SNPs) in the genes coding for the LXRs.

Interventions

BIOLOGICALWhole blood sampling

Whole blood sampling for SNP polymorphism analysis

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients undergoing C-section for a dystocia: 2 to 3 hours of stagnation in labor progress are observed (ie no increasing dilation, and uterine contractions less that 3-5 per 10 minutes) in spite of measures taken to overcome dystocia (oxytocin injection and artificial breaking of waters) * the child is alive * the child does not have apriori known malformations that could interfere with a vaginal birth * foetus in cephalic position * full term pregnancy (\>= 37 weeks of amenorrhea) * single birth * patient has signed consent * patient is affiliated with a social security system

Exclusion criteria

* vaginal birth * programmed C-section * C-section is chosen because the fetus has a cardia rhythm problem, and there is no stagnation in the labor process * multiple pregnancy * the child is in a breech position * premature birth (\<37 weeks amenorrhea) * in utero fetal death * fetal malformation known before birth that could interfere with a vaginal birth * non french-speaking patient (impossible to correctly inform the patient) * patient under guardianship

Design outcomes

Primary

Measure	Time frame	Description
The multi-loci genotype of the target DNA sequence.	Day 1	The polymorphisms of interest are the following SNPs: rs3758673, rs3758674, rs12221497, rs11039155, rs2279238, rs7120118, rs35463555, rs1052533, rs2248949, rs41432149, rs1405655, rs4802703.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026